December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

27.01 +0.99 (+3.80%)
Streaming Delayed Price Updated: 1:37 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 340,329
Open 25.82
Bid (Size) 26.91 (100)
Ask (Size) 27.04 (200)
Prev. Close 26.02
Today's Range 25.79 - 27.01
52wk Range 13.30 - 30.22
Shares Outstanding 41,151,111
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k ↗
The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
+73.8%
+73.8%
1 Month
+4.8%
+4.8%
3 Month
+24.1%
+24.1%
6 Month
+35.4%
+35.4%
1 Year
+26.5%
+26.5%

More News

Read More
S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours ↗
Via Stocktwits
Topics Government Stocks
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗
Via Stocktwits
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Resemble AI Unleashes Chatterbox Turbo: A New Era for Open-Source Real-Time Voice AI
Via TokenRing AI
Topics Artificial Intelligence Fraud Hacking
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Enliven Posts Loss Beat and Cash Surge ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
Via Benzinga
News headline image
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024 ↗
Via InvestorPlace
News headline image
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 ↗
Via InvestorPlace
News headline image
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program ↗
Via Benzinga
News headline image
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Via Benzinga

Frequently Asked Questions

Is Enliven Therapeutics, Inc. - Common Stock publicly traded?
Yes, Enliven Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Enliven Therapeutics, Inc. - Common Stock trade on?
Enliven Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enliven Therapeutics, Inc. - Common Stock?
The ticker symbol for Enliven Therapeutics, Inc. - Common Stock is ELVN on the Nasdaq Stock Market
What is the current price of Enliven Therapeutics, Inc. - Common Stock?
The current price of Enliven Therapeutics, Inc. - Common Stock is 27.01
When was Enliven Therapeutics, Inc. - Common Stock last traded?
The last trade of Enliven Therapeutics, Inc. - Common Stock was at 02/23/26 01:37 PM ET
What is the market capitalization of Enliven Therapeutics, Inc. - Common Stock?
The market capitalization of Enliven Therapeutics, Inc. - Common Stock is 1.11B
How many shares of Enliven Therapeutics, Inc. - Common Stock are outstanding?
Enliven Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.